Filament subsidiary Psilo Scientific manufactured the drug product on behalf of PharmAla for distribution to clinical trial customers and authorized patients. VANCOUVER, BC, April 11, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, and PharmAla Biotech Holdings Inc. (“PharmAla”…


Previous articlePT404 – Clusterbusters: The Horrors of Cluster Headaches and the Miracle of Psilocybin
Next articleatai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)